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Abstract: 
Substituted azafluorenones were synthesized from dihalogeno diaryl ketones under palladium catalysis 
by combining, in auto-tandem processes, Suzuki coupling and intramolecular arylation reactions. 
Different dihalogenated diaryl ketones, prepared by sequential deprotocupration-aroylation, were 
identified as suitable substrates to this purpose. Conditions were identified to allow successful 
syntheses of several 6-/7-arylated 4-azafluorenones, 1-substituted 4-azafluorenones, 2-phenyl-3-
azafluorenone and 4-phenyl-3-azafluorenone from 3-(bromobenzoyl)-2-chloropyridines, 3-benzoyl-4-
bromo-2-chloropyridines, 4-benzoyl-2,5-dichloropyridine and 4-benzoyl-2,3-dichloropyridine, 
respectively. Some of the synthesized compounds exhibit interesting biological properties. 
Introduction 
Many studies have been devoted to the access to azafluorenones, which are compounds of biological 
interest, for example in relation to their antifungal,
1
 antimicrobial,
2
 antimalarial,
2b,3
 and cytotoxic
2b,4
 
activities, or else for their role in the treatment of neurodegenerative disorders.
5
 Lithiations
6
 and 
multicomponent reactions
2d,4a,7
 can notably be cited among the modern synthetic methods by which to 
access them. In 2010, an approach was developed by Kraus and Kempema who used 2-bromoaryl 3-
pyridyl ketones, prepared by reaction of 3-pyridyllithiums with 2-bromobenzaldehydes followed by 
oxidation, in intramolecular Heck cyclization reactions.
2c
 In 2013, Ray and co-workers documented a 
two-step synthesis. Indeed, due to the facile oxidation of the corresponding α-aryl-2-bromo-3-
pyridylmethanols, they successfully performed both oxidation and cyclization reactions within one 
palladium-catalyzed step.
8
 
In the course of the development of 2,2,6,6-tetramethylpiperidido (TMP) bases for the deprotonative 
metalation of aromatic compounds,
9
 we have developed the use of (TMP)2CuLi·LiCl, prepared in situ 
from CuCl and LiTMP (2 equiv).
10
 Among the advantages of this lithiocuprate base, one can cite its 
possible use at room temperature and the possible trapping of the formed arylmetal species by aroyl 
 3 
chlorides to directly afford ketones. We have showed that, when applied to the synthesis of 2-chloro 
diaryl ketones, this method could be combined with direct arylation through C-H bond activation by 
intramolecular transition metal-catalysis,
11
 to afford azafluorenones and related compounds in two 
steps.
12
 Recently, we could achieve the synthesis of substituted azafluorenones by combining 
cyclization with cross-couplings such as Suzuki
13
 and Heck
14
 reactions in auto-tandem
15
 processes 
starting from diaryl ketones suitably substituted by two halogeno groups.
16
 Herein, the details of our 
synthetic investigations, including the testing of a large range of substrates, and the biological 
evaluation of the prepared compounds for their antibacterial, antifungal, antimalarial and cytotoxic 
activity are described. 
Results and Discussion 
The starting dihalogeno aroylpyridines were synthesized by deprotocupration-aroylation, as 
previously described.
10
 Upon treatment by the lithiocuprate (TMP)2CuLi·LiCl, generated in situ from 
CuCl and LiTMP (2 equiv), in tetrahydrofuran (THF) containing N,N,N’,N’-
tetramethylethylenediamine (TMEDA) at room temperature for 2 h, the different chloropyridines were 
regioselectively deprotocuprated; their subsequent trapping with aroyl chlorides in general afforded the 
expected ketones. In the case of 2-chloro-4-iodopyridine, the arylcuprate proved unstable before the 
conditions required to perform its trapping (Table 1). 
Table 1. Deprotocupration of 2-chloropyridines using in situ prepared (TMP)2CuLi·LiCl followed by 
aroylation.10c 
1) (TMP)2CuLi·LiCl (1 equiv)
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c 
a
 Yield after purification by column chromatography. The rest is in general starting material. 
b
 Trapping step 
performed at 60 °C. 
c
 Estimated 7% yield by performing the trapping step at rt; degradation at higher 
temperature. 
We first focused on the synthesis of 4-azafluorenones substituted on their phenyl ring starting from 2-
chloro-3-(halogenobenzoyl)pyridines and using palladium-catalyzed Suzuki coupling-intramolecular 
arylation auto-tandem reactions (Scheme 1, Table 2). 
N
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Pd catalysis
C-X arylation
C-H arylation
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Scheme 1. Possible synthesis of 4-azafluorenones substituted on their phenyl ring using palladium-
catalyzed double arylation. 
In our previous study aimed at cyclizing 3-benzoyl-2-chloropyridines to 4-azafluorenones,
12
 we 
employed a protocol inspired by conditions described for the cyclization of 2-chloro diaryl amines to 
carbazoles.
17
 This protocol used catalytic amounts of Pd(OAc)2 as transition metal source, electron-rich 
and bulky trialkyl phosphine Cy3P (Cy = cyclohexyl) as ligand, and K2CO3 as base, in DMF at 130 °C. 
Since similar conditions are suitable to perform Suzuki coupling reactions,
13
 we decided to attempt 
their use for the Suzuki coupling-intramolecular arylation of 3-(4-chlorobenzoyl)-2-chloropyridine (1-
Cl). We had previously observed the formation of bare 4-azafluorenone from 1-Cl (dechlorination) 
under these conditions;
12
 by performing the reaction in the presence of phenylboronic acid, we obtained 
a mixture containing expected 6-phenyl-4-azafluorenone (7a), but in a yield<15% due to the 
competitive formation of 2-phenyl-3-(4-phenylbenzoyl)pyridine (bis-coupled product, about 33% yield) 
and other (unidentified) coupled and/or dechlorinated products (entry 1). The Suzuki coupling being 
non-regioselective from 1-Cl, it was decided to rather involve 3-(4-bromobenzoyl)-2-chloropyridine (1-
 5 
Br) in the reaction. Under the same reaction conditions, the functionalized tricycle 7a was this time 
isolated in 91% yield (entry 2). 
It proved possible to extend the reaction to other arylboronic acids such as 4-hydroxyphenylboronic 
acid (entry 3), 3-thienylboronic acid (entry 4), and 2-benzo[b]thienylboronic acid (entry 5), and thus 
synthesize the corresponding 6-substituted 4-azafluorenones 7b-d in 41, 80 and 60% yield, 
respectively. The structures of the tricycles 7c and 7d were identified unambiguously by X-ray 
diffraction (Figure 1, left and middle). 
In contrast, using 2-furylboronic acid (entry 6) and 2,4-dimethoxy-5-pyrimidylboronic acid (entry 7) 
did not lead to the expected products. With the former, the main product was identified by gas 
chromatography (GC) as being 3-(4-(2-furyl)benzoyl)pyridine, i.e. the dechlorinated Suzuki coupling 
product. With the latter, 2-chloro-3-(4-(2,4-dimethoxy-5-pyrimidyl)benzoyl)pyridine, i.e. the Suzuki 
coupling product, proved by GC to be the main product whereas the expected derivative 7e was only 
detected (yield<15%) but could not be isolated.  
Starting from 3-(4-bromobenzoyl)-2-chloro-6-(trifluoromethyl)pyridine (4) and phenylboronic acid, 
the expected azafluorenone 8a was formed in 51% yield (entry 8). This moderate yield, when compared 
with that obtained using 1-Br, is at least partly due to the competitive formation (estimated 17% yield) 
of the bis-coupled product, 2-phenyl-3-(4-phenylbenzoyl)-6-(trifluoromethyl)pyridine. The 
trifluoromethyl group could be responsible, by its electron-withdrawing effect, for the competitive 
cross-coupling observed on the pyridine ring. The formation of the product resulting from a double 
Suzuki coupling suggests a Suzuki cross-coupling reaction easier than the C-H arylation giving the 
azafluorenone. 
3-(3-Bromobenzoyl)-2-chloropyridine (2) was next involved in the reaction with phenylboronic acid 
in order to see if a regioselective cyclization could be reached. In this case, both 7-phenyl-4-
azafluorenone (9a, 30% yield) and 2-chloro-3-(3-phenylbenzoyl)pyridine (9a’, 41% yield) were isolated 
(entry 9), also suggesting a Suzuki coupling prior to cyclization. The compound 9a was the only 
 6 
azafluorenone obtained, showing a complete regioselectivity for the position far from the phenyl 
substituent (Figure 1, right). Using 4-hydroxyphenylboronic acid similarly led to the corresponding 
azafluorenone 9b in a moderate 41% yield (entry 10). 
Table 2. Suzuki coupling-intramolecular arylation from the dihalides 1-4. 
ArB(OH)2 (1 equiv)
Pd(OAc)2 (5 mol%)
Cy3P·HBF4 (10 mol%)
K2CO3 (2 equiv)
DMF, 130 °C, 24 h
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a
 After purification by column chromatography. 
b
 2-Phenyl-3-(4-phenylbenzoyl)pyridine (about 33% yield) and 
other (unidentified) coupled and/or dechlorinated products were also formed. 
c
 The rest was starting material. 
d
 3-
(4-(2-Furyl)benzoyl)pyridine was identified by GC as the main product. 
e
 The product 7e could not be isolated; 2-
chloro-3-(4-(2,4-dimethoxy-5-pyrimidyl)benzoyl)pyridine was identified by GC as the main product. 
f
 2-Phenyl-3-
(4-phenylbenzoyl)-6-(trifluoromethyl)pyridine was also formed in estimated 17% yield. 
g
 2-Chloro-3-(3-
phenylbenzoyl)pyridine (9a’) was also isolated in 41% yield. h In addition to 10a’ (Scheme 2, 23% yield), three 
products resulting from mono (non-regioselective) and bis Suzuki cross-coupling were identified by GC, but no 4-
azafluorenone. 
i
 In addition to 10a’ (Scheme 2, 21% yield), 2-phenyl-3-(2-phenylbenzoyl)pyridine (about 21% 
yield) was also formed. 
When 2-chloro-3-(2-chlorobenzoyl)pyridine (3-Cl) was involved in the reaction with phenylboronic 
acid, a mixture of products was obtained. Three products resulting from mono (non-regioselective) and 
bis Suzuki cross-coupling were identified by GC, but no 4-azafluorenone. Indeed, the cyclized product 
that could be isolated in 23% yield rather proved to be the aza 9H-tribenzo[a,c,e]cyclohepten-9-one 
 7 
10a’ (entry 11, Scheme 2). The latter could result from a Suzuki cross-coupling followed by an 
intramolecular direct arylation between the phenyl group thus introduced and the second halogen. The 
ketone 10a’ was also isolated starting from 2-chloro-3-(2-bromobenzoyl)pyridine (3-Br), this time in 
21% yield together with 8-phenyl-4-azafluorenone (10a, Figure 1, about 31% yield) and 2-phenyl-3-(2-
phenylbenzoyl)pyridine (about 21% yield) (entry 12). 
  
Scheme 2. Side compound 10a’ obtained from 3 and ORTEP diagram (50% probability). 
   
Figure 1. ORTEP diagram (50% probability) of 7c, 7d and 10a. 
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Scheme 3. Possible synthesis of 4-azafluorenones substituted on their pyridine ring using palladium-
catalyzed double functionalization. 
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Also using palladium-catalyzed Suzuki coupling-intramolecular arylation auto-tandem reactions, we 
next focused on the synthesis of 4-azafluorenones substituted on their pyridyl ring by starting from 
different 3-benzoyl-2-chloro halogenopyridines (Scheme 3). 
Our first goal was to identify a new method to synthesize onychine (R = 1-Me), an alkaloid endowed 
with anticandidal activity,
1a
 as well as analogs, in order to evaluate them for their biological activity. 
Ray and co-workers recently reported the direct palladium-catalyzed conversion of α-aryl-2-bromo-3-
pyridylmethanols into 4-azafluorenones by oxidative intramolecular Heck cyclization using catalytic 
Pd(OAc)2 and NaOAc (2.5 equiv) in DMF at 100 °C.
8
 Since we could not apply the deprotometalation-
aroylation sequence to 2-chloro-4-iodopyridine in order to prepare 3-benzoyl-2-chloro-4-iodopyridine 
(Table 1, entry 7), we first used these conditions to attempt Suzuki coupling-oxidation-intramolecular 
arylation auto-tandem reactions from α-aryl-2-chloro-4-iodo-3-pyridylmethanols. 
By starting from 2-chloro-4-iodopyridine,
18
 deprotolithiation using LiTMP (1 equiv) in THF at -70 
°C furnished, after subsequent trapping with 4-anisaldehyde, the expected alcohol 11. Unfortunately, 
applying the conditions optimized by Ray and co-workers in the presence of phenylboronic acid only 
afforded 2-chloro-3-(4-methoxybenzoyl)-4-phenyl pyridine (oxidized monocoupled product) and its 
dechlorinated derivative. Under the conditions used in Table 2, oxidation proved incomplete and 
cyclization was not observed. Replacing K2CO3 by KOAc led to complete oxidation but inefficient 
cyclization (expected azafluorenone formed in a yield < 5%) and competitive dechlorination. Using 
methylboronic acid instead of phenylboronic acid led to similar results (Scheme 4). 
N
O
R
N NCl
I
Cl
I OH
OMe
1) LiTMP
THF, -70 °C, 1 h
2) 4-anisaldehyde
(70% yield) 11
X
OMe
R = Ph or Me  
Scheme 4. Attempted synthesis of 1-substituted 4-azafluorenones using a palladium-catalyzed Suzuki 
coupling-oxidation-intramolecular arylation auto-tandem reaction. 
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The direct conversion of 2-chloro-4-bromopyridine to 3-benzoyl-4-bromo-2-chloropyridines using 
deprotometalation-aroylation being possible (Table 1, entries 6 and 7), we applied the conditions used 
in Table 2 to these ketones (Table 3). By using Pd(OAc)2 as transition metal source, Cy3P as ligand and 
K2CO3 as base in DMF at 130 °C, the reaction performed from 3-benzoyl-4-bromo-2-chloropyridine (5-
Br) in the presence of phenylboronic acid led to 1-phenyl-4-azafluorenone (12a) in 73% yield (entry 1). 
Nevertheless, modulating the reactants nature showed that the reaction result was dependent on the 
nature of the arylboronic acids. By using 4-methoxyphenylboronic acid, the expected 1-substituted 4-
azafluorenone 12b was also isolated, but in a lower 52% yield (Figure 2). This result could be due to a 
less efficient cyclization, uncyclized 3-benzoyl-2-chloro-4-(4-methoxyphenyl)pyridine (Suzuki 
coupling product, 12b’) being also isolated in 24% yield (entry 2). In the case of 4-aminophenylboronic 
acid, no 1-substituted 4-azafluorenone was detected by GC analysis of the crude, but only 2,4-bis(4-
aminophenyl)-3-benzoylpyridine (resulting from a double Suzuki coupling) and 4-(4-aminophenyl)-3-
benzoyl-2-chloropyridine (corresponding to the uncyclized product) (entry 3). These results show that 
the presence of an electron-donating group on the phenyl substituent at the 4 position of the pyridine 
ring is not suitable for a subsequent palladium-catalyzed cyclization. Unfortunately, employing 3-
pyridylboronic acid furnished a complex mixture in which the expected 1-substituted 4-azafluorenone 
was not identified (entry 4). An azafluorenone was neither detected with 2-thienylboronic acid, but the 
corresponding uncyclized Suzuki coupling product 12c’, which was isolated in 49% yield (entry 5). In 
the case of 2-benzo[b]thienylboronic acid, a complex mixture was produced, but from which the 
expected 1-substituted 4-azafluorenone 12d could be isolated in 10% yield (entry 6). By turning to 
methylboronic acid, it proved possible to generate onychine (1-methyl-4-azafluorenone, 12e), an 
alkaloid endowed with anticandidal activity.
1a
 The moderate 52% yield obtained is due to the 
competitive formation of the bis-coupled product (about 11% yield) and to a difficult palladium-
catalyzed cyclization, as demonstrated by the detection by GC of 3-benzoyl-2-chloro-4-methylpyridine 
(about 7% yield) (entry 7). That the nature of the substituents has an impact on the course of the 
 10 
reaction was also evidenced by performing the reaction from 4-bromo-2-chloro-3-(3-
methoxybenzoyl)pyridine (6); in the presence of methylboronic acid, the reaction did not provide any 
more an azafluorenone, but the uncyclized Suzuki coupling product 13e’ (entry 8). Attempts to cyclize 
2-chloro-3-(3-methoxybenzoyl)-4-methylpyridine (13e’) in a separate reaction under the same reaction 
conditions neither proved successful. 
Table 3. Suzuki coupling-intramolecular arylation from the dihalides 5-Br and 6. 
RB(OH)2 (1 equiv)
Pd(OAc)2 (5 mol%)
Cy3P·HBF4 (10 mol%)
K2CO3 (2 equiv)
DMF, 130 °C, 24 h
N Cl
O
N
OBr
H or OMe
H or OMe
R
 
Entry Substrate(-X) Product (R) Yield
a
 (%) 
1 
2 
3 
4 
5 
6 
7 
5-Br 
5-Br 
5-Br 
5-Br 
5-Br 
5-Br 
5-Br 
N Cl
OBr
 
12a (Ph) 
12b (C6H4-4-OMe) 
- (C6H4-4-NH2) 
- (3-pyridyl) 
- (2-thienyl) 
12d (2-benzo[b]thienyl) 
12e (Me) 
N
O
R
 
73 
52
b
 
-
c
 
-
d
 
-
e
 
10
f 
52
g
 
8 6 
N Cl
OBr
OMe
 
- (Me) 
N
O
R
OMe
 
-
h
 
a
 After purification by column chromatography. 
b
 3-Benzoyl-2-chloro-4-(4-methoxyphenyl)pyridine (12b’) was 
also isolated in 24% yield. 
c
 Only 3-benzoyl-2,4-bis(4-aminophenyl)pyridine and 4-(4-aminophenyl)-3-benzoyl-2-
chloropyridine were identified by GC. 
d
 A complex mixture was obtained. 
e
 Only 3-benzoyl-2-chloro-4-(2-
thienyl)pyridine (12c’) was isolated in 49% yield. f Only this product was isolated from a complex mixture. g 3-
Benzoyl-2-chloro-4-methylpyridine and 3-benzoyl-2,4-dimethylpyridine were also detected by GC in the crude. 
h
 
Only 2-chloro-3-(3-methoxybenzoyl)-4-methylpyridine (13e’) was isolated in 35% yield. 
 
Figure 2. ORTEP diagrams (50% probability) of compound 12b. 
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In order to reach other analogs of onychine, deprotocupration-aroylation was first attempted from 2-
chloro-4-methylpyridine. Unfortunately, reaction of 2-chloro-4-methylpyridine under the conditions 
used in Table 1 and using benzoyl chloride as electrophile did not lead to the 3-pyridyl ketone, but to a 
mixture of unidentified compounds. 
Compared with 3-benzoyl-4-bromo-2-chloropyridine (5-Br), 3-benzoyl-2,4-dichloropyridine (5-Cl) 
behaved differently. Indeed, under the conditions of Table 3 and in the presence of phenylboronic acid, 
the azafluorenone 12a was not obtained. Instead, due to a favored Suzuki coupling at the pyridine 2 
position,
19
 1-phenyl-2-azafluorenone was rather identified, but in a low 11% yield due to the 
competitive formation of 3-benzoyl-2,4-diphenylpyridine (double Suzuki coupling, 26% yield), 3-
benzoyl-4-chloro-2-phenylpyridine (uncyclized product, 12% yield) and 3-benzoyl-2-phenylpyridine 
(dechlorination of the latter, 3% yield) (Scheme 5, left). In the case of 3-benzoyl-2,6-dichloropyridine 
(14), using phenylboronic acid demonstrated a favored Suzuki coupling at the less hindered pyridine 6 
position, as shown by the formation of 3-phenyl-4-azafluorenone (15, 38% yield), which was identified 
by X-ray diffraction.
16
 Nevertheless, such a reactivity difference is small, and the bis-coupled product 
was competitively formed in 52% yield (Scheme 5, right). We thus turned to 2,3- and 2,5-
dichloropyridines, which generally react regioselectively in Suzuki cross-coupling reactions to afford 
the 2-functionalized derivatives.
20 
NCl Cl
Ph
O
N Cl
Ph
OCl
favored
Suzuki
coupling
competitive
Suzuki
coupling
favored
Suzuki
coupling
competitive
Suzuki
coupling
 
Scheme 5. Uncomplete regioselectivity observed for Suzuki coupling on the dichlorides 5-Cl and 14. 
From 4-benzoyl-2,3-dichloropyridine (16), applying the same protocol in the presence of 
phenylboronic acid furnished 4-phenyl-3-azafluorenone (17, Figure 3) in 70% yield. The product 
 12 
resulting from a double Suzuki coupling was also identified, but this time in about 15% yield. 
Similarly, 2-phenyl-3-azafluorenone (18) was synthesized from 4-benzoyl-2,5-dichloropyridine (19) in 
64% yield (Scheme 6). 
N Cl 18
19
Cl
O
N Ph
O
N Cl 17
16
O
N Ph
O
Cl
PhB(OH)2 (1 equiv)
Pd(OAc)2 (5 mol%)
Cy3P·HBF4 (10 mol%)
K2CO3 (2 equiv)
DMF, 130 °C, 24 h
(70% yield)
PhB(OH)2 (1 equiv)
Pd(OAc)2 (5 mol%)
Cy3P·HBF4 (10 mol%)
K2CO3 (2 equiv)
DMF, 130 °C, 24 h
(64% yield)
 
Scheme 6. Suzuki coupling-intramolecular arylation from the dichlorides 16 and 18. 
 
Figure 3. ORTEP diagrams (50% probability) of compound 17. 
Our experimental findings show that Suzuki coupling precedes intramolecular arylation during 
azafluorenone formation. To rationalize the results obtained for these cyclizations, we have performed 
quantum chemical calculations. One can predict that oxidative addition is quite related to the partial 
positive charge on the carbon bearing the chlorine, as it is for nucleophilic substitution. We thus 
accounted for this positive charge by linking it to the corresponding 
1
H NMR chemical shift of the 
dechlorinated substrate, as shown by Handy and Zhang.
21
 As far as the C-H activation step is 
concerned, it notably depends on the corresponding CH acidity. Thus, in addition to the electrophilicity 
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measure of the carbon bearing chlorine, we also calculated the acidity at the cyclization site of the 
phenyl ring for the expected Suzuki coupling products using a homodesmic reaction protocol effective 
for azines
10c,22
 (Table 4). 
Table 4. Calculated values of pKa(THF) for selected substrates, and 
1
H NMR chemical shift for their 
dechlorinated analogues. 
Entry Substrate δ (C2, X = H) pKa (C2’, C6’, X = Cl) 
1 
N X
O
2
2'  
9.24 38.6 (C2’) 
2 
N X
O
2
2'
Ph 
9.29 38.4 (C2’) 
3 
N X
O
2
6'
S
2'
 
9.26 37.2, 39.6 (C2’, C6’)
a
 
4 
N X
O
2
6'
O
2'
 
9.26 37.9, 40.0 (C2’, C6’)
a
 
5 
N X
O
2
6'
Ph
2'  
9.17 38.1, 40.7 (C2’, C6’) 
6 
N X
O
2
6'
2"
 
9.36 38.8, 43.2 (C6’, C2”) 
7 
N X
O
2
2'
Ph
 
8.85 39.1 (C2’) 
8 
N X
O
2
2'
S
 
8.85 38.4 (C2’) 
9 
N X
O
2
2'
Me
 
8.93 39.9 (C2’) 
10 
N X
O
2
2'
Me
OMe
6'
 
8.91 38.6, 40.8 (C2’, C6’) 
a
 Two values are given when distinct products can be obtained as a result of internal rotation. 
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Because of the strict steric requirements for cyclization, we only considered here the CH acidities of 
the suspicious sites, omitting the others. It is obvious that some of these compounds exist in form of 
several rotamers, and the data from Table 4 refer to the most stable ones (see Supplementary data). In 
general, these polycycles demonstrate a trend, which is present in phenyl rings (rather than pyridyl) to 
be in conjugation with a carbonyl moiety. Unfortunately, in our set of compounds, the reaction center is 
quite remote from the substituent that is changed. This leads to their effect attenuation, and quantities 
discussed (δ, pKa) are varying in a narrow range. Nevertheless, their change is quite logical with the 
electron-withdrawing or -donating properties (in particular, see entries 7-10). 
We have previously demonstrated that CH acidities
10c,22
 are an essential factor in deprotometallation 
of azines including biaryls. In the tandem process under consideration, one can see that the pKa`s 
contribution is not so important, but the electron-withdrawing groups still favor the reaction (e.g. see 
Table 2, entries 2-5; Table 3, entries 1,2). 
When compared with 3-benzoyl-2-chloropyridine (Table 4, entry 1),
12b
 the phenyl- and 2-
benzo[b]thienyl-substituted derivatives coming from 1-Br (entries 2 and 3), which have nearly the same 
partial positive charges at C2 and CH acidities at C2’, are converted into the tricycles 7a and 7d in 
similar (good) yields. The reason why the furyl-substituted derivative coming from 1-Br (entry 4) only 
furnished the dechlorinated Suzuki coupling product 3-(4-(2-furyl)benzoyl)pyridine does not seem to be 
in relation with these quantities. 
To rationalize the lower reactivity of the phenyl-substituted derivative coming from 2 (entry 5), one 
can advance a lower partial positive charge at C2 when estimated from the 
1
H NMR chemical shift of 
the dechlorinated substrate. On the same basis, a high partial positive charge at C2 is evidenced from 
the phenyl-substituted derivative coming from 3-Br (entry 6). This could be at the origin of the 
formation of the bis-coupled product 2-phenyl-3-(2-phenylbenzoyl)pyridine. The latter appears as a 
more likely precursor of 10a’ if we consider the low CH acidity at C2” of the calculated substrate (entry 
6). 
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Compared with 3-benzoyl-2-chloropyridine (entry 1), the corresponding 4-phenyl (entry 7), 4-(2-
benzo[b]thienyl) (entry 8) and 4-methyl (entry 9) derivatives show lower partial positive charges at C2 
when estimated from the 
1
H NMR chemical shift of the dechlorinated substrates. In the case of 4-
phenyl (entry 7) and 4-methyl (entry 9), it is combined with lower CH acidities at C2’ but with nearly 
no alteration of the cyclization yield. Thus, the complex mixture obtained from the 4-(2-
benzo[b]thienyl) (entry 8) has to be explained differently, and could result from possible coordination 
of palladium by the sulfur-containing ring. The reluctance to react of 2-chloro-3-(3-methoxybenzoyl)-4-
methylpyridine (entry 10) could result from both a sterically congested position at C2’ and a lower CH 
acidity at C6’. 
Biological evaluation 
Because of structural similarity with natural azafluorenone antimicrobial agents such as onychine,
1a,2b
 
the synthesized compounds 7b-d, 9a’, 9b, 10a’, 12a,b, 17 and 18 were screened for their antibacterial 
activity against Gram-negative (Escherichia coli) and Gram-positive (Staphylococcus aureus) bacteria, 
and for their antifungal activity against Candida albicans (Table 5). It was found that all the tested 
compounds have high potent antifungal activity against Candida albicans, more than the reference drug 
(nystatin). For the antibacterial activity, all the compounds except 9b and 18 have high to moderate 
effect against Gram-positive bacteria (Staphylococcus aureus) and, in case of Gram-negative bacteria 
(Escherichia coli), the compounds 9b, 12a,b and 18 exhibit high activities and the compounds 9a’, 
10a’ and 17 moderate activities whereas the compounds 7b-d were found to have no effect. 
Table 5. Bactericidal and fungicidal activity of the compounds 7b-d, 9a’, 9b, 10a’, 12a,b, 17, 18 and 
ciprofloxacin and nystatin.
a
 
Entry Compound Escherichia coli Staphylococcus aureus Candida albicans 
1 
2 
3 
4 
5 
6 
7b 
7c 
7d 
9a’ 
9b 
10a’ 
- 
- 
- 
++ 
++++++ 
+++ 
+++++ 
+++ 
++++ 
++++ 
- 
++++ 
+++++ 
++++++ 
++++++ 
++++++ 
++++++ 
++++++ 
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7 
8 
9 
10 
11 
12 
12a 
12b 
17 
18 
ciprofloxacin 
nystatin 
++++++ 
++++ 
+++ 
++++++ 
++++ 
- 
++ 
+++ 
+++ 
- 
++++ 
- 
++++++ 
++++++ 
++++++ 
++++++ 
- 
++++ 
a
 The diameters of zones of inhibition are given in mm. Stock solution: 5 μg in 1 mL of DMF; 0.1 mL of stock 
solution in each hole of each paper disk. +: <15 mm; ++: 15–24 mm; +++: 25–34 mm; ++++: 35–44 mm, etc. 
Onychine (12e) being one of the main alkaloids of the antimalarial plant Polyalthia debilis,
2b
 the 
synthesized compounds 8a, 10a’, 12a,b,b’,d,e and 18 with structural analogy to onychine were also 
screened for their antimalarial activity (Table 6). Onychine (12e) presented only a weak activity (IC50 = 
52.4 μM) against the cloroquine sensitive strain 3D7 of Plasmodium falciparum. The majority of the 
tested compounds presented a similar or slightly higher activity to onychine. Only compounds 8a and 
18, with IC50 of respectively 13.8 and 4.8 μM, were clearly highly active. According to Pink et al., a 
compound could be considered as an antiparasitic hit if its activity in vitro is ≤ 1 μg/mL and if it bears a 
selectivity towards mammalian cells of about tenfold.
23
 The compound 18, bearing no cytotoxicity at 10 
μM and a quite interesting antiplasmodial activity (4.8 μM – 1.2 μg/mL), meets this criteria and could 
constitute an interesting antimalarial lead for further chemical modifications. 
Table 6. Antimalarial activity of the compounds 8a, 10a’, 12a,b,b’,d,e and 18. 
Entry Compound IC50 (µg/mL) IC50 (µM) 
1 
2 
3 
4 
5 
6 
7 
8 
8a 
10a’ 
12a 
12b 
12b’ 
12d 
12e 
18 
4.51 
10.5 
6.37 
7.64 
10.3 
10.9 
10.2 
1.23 
13.8 
40.8 
24.7 
26.6 
31.8 
34.9 
52.4 
4.78 
Finally, a study has been carried out to investigate the cytotoxic potential of the derivatives 7b-d, 9b, 
and 12a,b (Table 7). The antiproliferative activity of the derivatives was determined using breast cancer 
cell line MCF-7, which is an invasive differentiated mammary epithelial breast cancer cell line used 
worldwide to screen and compare the antiproliferative activity of new molecules vs standard anticancer 
 17 
compounds. Among the molecules tested, the compounds 7c,d containing a thienyl ring showed a 
strong antiproliferative activity, higher to that exhibited by doxorubicin, whereas the compound 12b 
showed a similar activity. 
Table 7. Cytotoxic activity of the compounds 7b-d, 9b, and 12a,b and doxorubicin against MCF-7.
a
 
Entry Compound IC50 (µg/mL) 
1 
2 
3 
4 
5 
6 
7 
7b 
7c 
7d 
9b 
12a 
12b 
doxorubicin 
4.43 
3.38 
2.78 
7.43 
8.48 
3.83 
3.53 
a
 IC50 is defined as the concentration which results in a 50% decrease in the cell number as 
compared with that of the control structures in the absence of an inhibitor. 
Conclusion 
In summary, different azafluorenones endowed with potential biological activities were synthesized 
from dihalogenated diaryl ketones by palladium-catalyzed Suzuki coupling-intramolecular arylation 
auto-tandem reactions. The required diaryl ketones were previously generated by sequential 
deprotocupration-aroylation. From 3-benzoyl-2-chloropyridines halogenated on their phenyl ring, 
several 6-arylated and 7-arylated 4-azafluorenones were prepared. Onychine (1-methylated 4-
azafluorenone) and 1-arylated analogs were synthesized by involving 3-benzoyl-4-bromo-2-
chloropyridine in the auto-tandem process. Finally, the access to 2-arylated and 4-arylated 3-
azafluorenones proved possible in two steps from commercially available 2,5-dichloropyridine and 2,3-
dichloropyridine. 
4. Experimental Section 
4.1. General. All reactions were performed in Schlenk tubes under an argon atmosphere. THF was 
distilled over sodium/benzophenone. DMF was dried over CaH2 and distilled before use. Liquid 
chromatography separations were achieved on silica gel Merck-Geduran Si 60 (63-200 μm). Nuclear 
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Magnetic Resonance spectra were acquired using Bruker AC-300 spectrometer (300 MHz and 75 MHz 
for 
1
H and 
13
C respectively). 
1H chemical shifts (δ) are given in ppm relative to the residual solvent 
peak, and 
13
C chemical shifts relative to the central peak of the solvent signal.
24
 High resolution mass 
spectrometry measurements were performed at the Centre Régional de Mesures Physiques de l'Ouest 
(CRMPO) in Rennes. 3-(4-Bromobenzoyl)-2-chloropyridine (1-Br), 2-chloro-3-(3-
bromobenzoyl)pyridine (2), 2-chloro-3-(4-iodobenzoyl)pyridine (1-I), 3-(4-bromobenzoyl)-2-chloro-6-
(trifluoromethyl)pyridine (4), 2-chloro-3-benzoyl-4-bromopyridine (5-Br), 8-phenyl-5H-indeno[1,2-
b]pyridin-5-one or 6-phenyl-4-azafluorenone (7a), 8-(4-hydroxyphenyl)-5H-indeno[1,2-b]pyridin-5-one 
or 6-(4-hydroxyphenyl-4-azafluorenone (7b), 8-phenyl-2-(trifluoromethyl)-5H-indeno[1,2-b]pyridin-5-
one or 6-phenyl-3-(trifluoromethyl)-4-azafluorenone (8a), 7-phenyl-5H-indeno[1,2-b]pyridin-5-one or 
7-phenyl-4-azafluorenone (9a), 2-chloro-3-(3-phenylbenzoyl)pyridine (9a’), 7-(4-hydroxyphenyl)-5H-
indeno[1,2-b]pyridin-5-one or 7-(4-hydroxyphenyl-4-azafluorenone (9b), 4-phenyl-5H-indeno[1,2-
b]pyridin-5-one or 1-phenyl-4-azafluorenone (12a), 3-benzoyl-2-chloro-4-(4-methoxyphenyl)pyridine 
(12b’), 4-methyl-5H-indeno[1,2-b]pyridin-5-one or 1-methyl-4-azafluorenone (onychine, 12e), 2-
methyl-5H-indeno[1,2-b]pyridin-5-one or 3-phenyl-4-azafluorenone (15), and 3-phenyl-5H-indeno[1,2-
c]pyridin-5-one or 2-phenyl-3-azafluorenone (18) were obtained as described in the preliminary 
communication.
16
 
X-ray Crystallography. The samples were studied with graphite monochromatized Mo-K radiation 
( = 0.71073 Å). The X-ray diffraction data were collected using APEXII, Bruker-AXS diffractometer 
at T = 150(2) K. All structures were solved by direct methods using the SIR97 program,
25
 and then 
refined with full-matrix least-square methods based on F
2
 (SHELX-97)
26
 with the aid of the WINGX 
program.
27
 All non-hydrogen atoms were refined with anisotropic atomic displacement parameters. H 
atoms were finally included in their calculated positions. Molecular diagrams were generated by 
ORTEP-3 (version 2.02).
27
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4.2. General procedure 1: Deprotonation using the lithium-copper base prepared from CuCl (1 
equiv) and LiTMP (2 equiv) before trapping with an aroyl chloride. A stirred cooled (0 °C) 
solution of LiTMP prepared at 0 °C in THF (6 mL) from 2,2,6,6-tetramethylpiperidine (1.7 mL, 10 
mmol) and BuLi (1.6 M hexanes solution, 10 mmol) was treated with TMEDA (0.77 mL, 5.0 mmol) 
and CuCl (495 mg, 5.0 mmol). The mixture was stirred for 15 min at 0 °C before introduction of the 
required substrate (5 mmol). After 2 h at rt, a solution of the required aroyl chloride (10 mmol) in THF 
(3 mL) was added. The mixture was stirred at rt or 60 °C overnight before addition of a 1M aqueous 
solution of NaOH (20 mL) and extraction with Et2O (2 x 20 mL). After washing the organic phase with 
an aqueous saturated solution of NH4Cl (10 mL) and drying over anhydrous Na2SO4, the solvent was 
evaporated under reduced pressure, and the product was isolated after purification by flash 
chromatography on silica gel (the eluent is given in the product description). 
4.2.1. 2-Chloro-3-(2-bromobenzoyl)pyridine (3-Br) was prepared from 2-chloropyridine according 
to the general procedure 1 and isolated (eluent: heptane/AcOEt 9/1) as a yellow oil (yield: 64%): 
1
H 
NMR (300 MHz, acetone-d6) 7.52-7.63 (m, 4H), 7.74-7.78 (m, 1H), 8.0 (dd, 1H, J = 7.6 and 1.9 Hz), 
8.60 (d, 1H, J = 4.8 and 1.9 Hz); 
13
C NMR (75 MHz, acetone-d6) 120.9 (C), 124.0 (CH), 128.8 (CH), 
132.1 (CH), 134.2 (CH), 134.8 (C), 134.9 (CH), 140.0 (C), 140.8 (CH), 148.9 (C), 152.9 (CH), 193.9 
(C); HRMS (ASAP): calcd for C12H8
79
Br
35
ClNO ([M+H]
+
) 295.9478, found: 295.9480. 
4.2.2. 2-Chloro-4-bromo-3-(3-methoxybenzoyl)pyridine (6) was prepared from 4-bromo-2-
chloropyridine according to the general procedure 1 and isolated (eluent: heptane/AcOEt 9/1) as a pale 
yellow powder (yield: 31%): mp 118 °C; 
1
H NMR (300 MHz, CDCl3) 3.88 (s, 3H), 7.21 (ddd, 1H, J = 
8.2, 2.6 and 1.0 Hz), 7.25-7.28 (m, 1H), 7.37-7.42 (m, 1H), 7.47 (dd, 1H, J = 2.6 and 1.6 Hz), 7.57 (d, 
1H, J = 5.3 Hz), 8.33 (d, 1H, J = 5.3 Hz); 
13
C NMR (75 MHz, CDCl3) 55.6 (CH3), 113.1 (CH), 121.5 
(CH), 122.9 (CH), 126.9 (CH), 130.2 (CH), 131.8 (C), 135.9 (C), 136.1 (C), 148.1 (C), 150.1 (CH), 
160.3 (C), 191.2 (C); HRMS (ESI): calcd for C13H9
79
Br
35
ClNNaO2 ([M+Na]
+
) 347.94029, found: 
347.9405. 
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4.3. 2-Chloro-4-iodo-α-(4-methoxyphenyl)-3-pyridinemethanol (11). A stirred solution of LiTMP 
prepared at 0 °C in THF (6 mL) from 2,2,6,6-tetramethylpiperidine (1.7 mL, 10 mmol) and BuLi (1.6 
M hexanes solution, 10 mmol) was stirred for 15 min before introduction, at -70 °C, of 2-chloro-4-
iodopyridine
18
 (2.4 g, 10 mmol). After 1 h at -70 °C, a solution of 4-anisaldehyde (10 mmol) in THF (6 
mL) was added. The mixture was stirred overnight before addition of water (20 mL) and extraction 
with Et2O (2 x 20 mL). After washing the organic phase with an aqueous saturated solution of NH4Cl 
(10 mL) and drying over anhydrous Na2SO4, the solvents were evaporated under reduced pressure, and 
the product was isolated after purification by flash chromatography on silica gel (eluent: 
heptane/AcOEt 8/2) as a pale yellow powder (yield: 70%): mp 116 °C; 
1
H NMR (300 MHz, CDCl3) 
3.81 (s, 3H), 5.65 (s, 1H), 6.90 (dd, 2H, J = 6.6 and 2.1 Hz), 7.21 (dd, 2H, J = 6.6 and 2.1 Hz), 7.31 (t, 
1H, J = 1.0 Hz), 7.68 (t, 1H, J = 1.0 Hz), OH not seen; 
13
C NMR (75 MHz, CDCl3) 55.4 (CH3), 73.5 
(CH), 114.5 (2CH), 115.4 (C), 121.2 (CH), 128.3 (2CH), 131.3 (CH), 133.7 (C), 150.5 (C), 157.7 (C), 
159.8 (C); HRMS (ESI): calcd for C13H11
35
ClINNaO2 ([M+Na]
+
): 397.94208, found: 397.9424. 
4.4. General procedure 2: tandem reaction including Suzuki coupling. A degassed mixture 
containing K2CO3 (0.28 g, 2.0 mmol), Pd(OAc)2 (11 mg, 50 μmol, 5 mol%), Cy3P·HBF4 (37 mg, 0.10 
mmol, 10 mol%), the required ketone (1.0 mmol) and the required boronic acid (1.0 mmol) in DMF (4 
mL) was heated at 130 °C for 24 h. After filtration over a celite pad, washing using CH2Cl2 (3 x 10 
mL), and removal of the solvent under reduced pressure, the product was isolated after purification by 
flash chromatography on silica gel (the eluent is given in the product description). 
4.4.1. 8-(3-Thienyl)-5H-indeno[1,2-b]pyridin-5-one or 6-(3-thienyl)-4-azafluorenone (7c) was 
obtained from 1-Br and 3-thienylboronic acid using the general procedure 2 as described in the 
preliminary communication.
16
 X-ray diffraction data (CCDC 1405060): C16H9NOS, M = 263.30, 
monoclinic, space group P 21/c (I.T.#14), a = 3.88380(10), b = 23.6837(8), c = 12.9204(4) Å, β = 
90.1350(10) °, V = 1188.45(6) Å
3
, Z = 4, d = 1.472 g.cm
-3
, μ = 0.260 mm-1; a final refinement on F2 
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with 2699 unique intensities and 172 parameters converged at ωR(F2) = 0.1064 (R(F) = 0.0401) for 
2246 observed reflections with I > 2σ(I). 
4.4.2. 8-(2-Benzo[b]thienyl)-5H-indeno[1,2-b]pyridin-5-one or 6-(2-benzo[b]thienyl)-4-
azafluorenone (7d) was obtained from 1-Br and 3-(2-benzo[b]thienyl)boronic acid using the general 
procedure 2 as described in the preliminary communication.
16
 X-ray diffraction data (CCDC 1405061): 
C20H11NOS, M = 313.36, monoclinic, space group P 21/a (I.T.#14), a = 7.9224(2), b = 12.3724(4), c = 
14.9212(4) Å, β = 100.6070(10) °, V = 1437.57(7) Å3, Z = 4, d = 1.448 g.cm-3, μ = 0.228 mm-1; a final 
refinement on F
2
 with 3280 unique intensities and 208 parameters converged at ωR(F2) = 0.1008 (R(F) 
= 0.0379) for 2836 observed reflections with I > 2σ(I). 
4.4.3. 6-Phenyl-5H-indeno[1,2-b]pyridin-5-one or 8-phenyl-4-azafluorenone (10a) was obtained 
from 3-Br and phenylboronic acid using the general procedure 2. Identified by GC, its structure was 
confirmed by X-ray diffraction. X-ray diffraction data (CCDC 1405062): C18H11NO, M = 257.28, 
monoclinic, space group P 21/c (I.T.#14), a = 3.8865(6), b = 13.545(2), c = 23.472(4) Å, β = 93.828(7) 
°, V = 1232.9(3) Å
3
, Z = 4, d = 1.386 g.cm
-3
, μ = 0.086 mm-1; a final refinement on F2 with 2809 unique 
intensities and 181 parameters converged at ωR(F2) = 0.1721 (R(F) = 0.0723) for 1311 observed 
reflections with I > 2σ(I). 
4.4.4. 9H-Tribenzo[a,c,e]cyclohepten-9-one (10a’) was obtained from 3-Cl or 3-Br and 
phenylboronic acid using the general procedure 2 and isolated (eluent: heptane/AcOEt 9/1) as a pale 
yellow powder (yield: 23 or 21%): mp 134 °C; 
1
H NMR (300 MHz, CDCl3) 7.42 (dd, 1H, J = 7.8 and 
4.7 Hz), 7.5 (ddd, 1H, J = 7.5 and 1.2 Hz), 7.55-7.62 (m, 2H), 7.64-7.69 (m, 2H), 7.73 (dd, 1H, J = 7.7 
and 1.2 Hz), 7.76 (dd, 1H, J = 7.8 and 0.9 Hz), 8.05 (dd, 1H, J = 7.8 and 1.7 Hz), 8.17-8.22 (m, 1H), 
8.88 (dd, 1H, J = 4.7 and 1.7 Hz); 
13
C NMR (75 MHz, CDCl3) 122.9 (CH), 127.1 (CH), 128.4 (CH), 
128.6 (CH), 129.9 (CH), 130.0 (CH), 131.1 (CH), 131.6 (CH), 132.2 (CH), 135.8 (C), 136.2 (CH), 
136.5 (C), 137.5 (C), 138.0 (C), 141.7 (C), 151.7 (CH), 153.1 (C), 196.9 (C); HRMS (ASAP): calcd for 
C18H12NO ([M+H]
+
) 258.0919, found: 258.0919. X-ray diffraction data (CCDC 1405063): 
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8(C18H11NO), M = 2058.22, monoclinic, space group P c (I.T.#7), a = 7.4632(7), b = 22.339(2), c = 
30.083(3) Å, β = 96.373(5) °, V = 4984.5(8) Å3, Z = 2, d = 1.371 g.cm-3, μ = 0.085 mm-1; a final 
refinement on F
2
 with 17035 unique intensities and 1039 parameters converged at ωR(F2) = 0.3947 
(R(F) = 0.1468) for 10255 observed reflections with I > 2σ(I). 
4.4.5. 4-(4-Methoxyphenyl)-5H-indeno[1,2-b]pyridin-5-one or 1-(4-methoxyphenyl)-4-
azafluorenone (12b) was obtained from 5-Br and 4-methoxyphenylboronic acid using the general 
procedure 2 as described in the preliminary communication.
16
 X-ray diffraction data (CCDC 1405064): 
C19H13NO2, M = 287.30, orthorhombic, space group F 2 d d (I.T.#43), a = 3.8294(4), b = 27.387(3), c = 
52.389(5) Å, V = 5494.3(10) Å
3
, Z = 16, d = 1.389 g.cm
-3
, μ = 0.091 mm-1; a final refinement on F2 
with 1781 unique intensities and 200 parameters converged at ωR(F2) = 0.101 (R(F) = 0.0461) for 1378 
observed reflections with I > 2σ(I). 
4.4.6. 3-Benzoyl-2-chloro-4-(2-thienyl)pyridine (12c’) was obtained from 5-Br and 2-
thienylboronic acid using the general procedure 2 and isolated (eluent: heptane/AcOEt 9/1) as a pale 
yellow powder (yield: 49%): mp 102 °C; 
1
H NMR (300 MHz, CDCl3) 7.01 (dd, 1H, J = 5.1 and 1.4 
Hz), 7.25 (dd, 1H, J = 5.0 and 2.9 Hz), 7.3 (dd, 1H, J = 2.9 and 1.4 Hz), 7.34-7.43 (m, 3H), 7.55 (tt, 
1H, J = 6.8 and 1.3 Hz), 7.72-7.75 (m, 2H), 8.53 (br s, 1H); 
13
C NMR (75 MHz, CDCl3) 126.6 (CH), 
127.1 (CH), 127.5 (CH), 128.9 (C), 129.0 (2CH), 129.5 (2CH), 130.1 (CH), 134.3 (CH), 136.1 (C), 
136.6 (C), 138.0 (CH), 145.0 (C), 148.0 (C), 194.6 (C); HRMS (ASAP): calcd for C16H11
35
ClNOS 
([M+H]
+
) 300.0250, found: 300.0248. 
4.4.7. 4-(2-Benzo[b]thienyl)-5H-indeno[1,2-b]pyridin-5-one or 1-(2-benzo[b]thienyl)-4-
azafluorenone (12d) was obtained from 5-Br and 2-(benzo[b]thienyl)boronic acid using the general 
procedure 2 and isolated (eluent: heptane/AcOEt 9/1) as a pale yellow powder (yield: 10%): mp 186 
°C; 
1
H NMR (300 MHz, CDCl3) 7.41-7.46 (m, 3H), 7.49 (d, 1H, J = 7.4 Hz), 7.64 (t, 1H, J = 7.0 Hz), 
7.76 (dd, 1H, J = 7.3 and 0.7 Hz), 7.86-7.96 (m, 3H), 8.60 (br s, 1H), 8.70 (s, 1H); 
13
C NMR (75 MHz, 
CDCl3) 121.3 (CH), 122.3 (CH), 124.2 (CH), 125.1 (CH), 125.4 (CH), 126.4 (CH), 130.0 (CH), 131.6 
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(CH), 134.7 (C), 135.5 (CH), 136.5 (C), 140.2 (C), 140.7 (C), 191.3 (C), 2CH and 4C not seen; HRMS 
(ASAP): calcd for C20H12NOS ([M+H]
+
) 314.0640, found: 314.0639. 
4.4.8. 2-Chloro-3-(3-methoxybenzoyl)-4-methylpyridine (13e’) was obtained from 6 and 
methylboronic acid using the general procedure 2 and isolated (eluent: heptane/AcOEt 9/1) as a pale 
yellow powder (yield: 35%): mp 92 °C; 
1
H NMR (300 MHz, CDCl3) 2.22 (s, 3H), 3.87 (s, 3H), 7.17-
7.21 (m, 2H), 7.23-7.26 (m, 1H), 7.38 (t, 1H, J = 7.8 Hz), 7.46 (dd, 1H, J = 2.5 and 1.6 Hz), 8.36 (d, 
1H, J = 5.1 Hz); 
13
C NMR (75 MHz, CDCl3) 19.3 (CH3), 55.7 (CH3), 113.0 (CH), 121.3 (CH), 122.8 
(CH), 124.5 (CH), 130.2 (CH), 135.1 (C), 137.2 (C), 147.2 (C), 148.2 (C), 149.6 (CH), 160.4 (C), 
194.1 (C); HRMS (ESI): calcd for C14H12
35
ClNNaO2 ([M+Na]
+
) 284.0454, found: 284.0450. 
4.4.9. 1-Phenyl-5H-indeno[1,2-b]pyridin-5-one or 4-phenyl-3-azafluorenone (17) was obtained 
from 16 and phenylboronic acid using the general procedure 2 as described in the preliminary 
communication.
16
 X-ray diffraction data (CCDC 1405065): C18H11NO, M = 257.28, monoclinic, space 
group P 21/c (I.T.#14), a = 5.7543(5), b = 21.827(2), c = 10.2994(11) Å, β = 103.346(4) °, V = 
1258.7(2) Å
3
, Z = 4, d = 1.358 g.cm
-3
, μ = 0.085 mm-1; a final refinement on F2 with 2861 unique 
intensities and 181 parameters converged at ωR(F2) = 0.0942 (R(F) = 0.0446) for 1899 observed 
reflections with I > 2σ(I). 
4.5. In vitro antimicrobial and antifungal assays. Applying the agar plate diffusion technique,
28
 
the compounds were screened in vitro for their bactericidal activity against Gram-positive bacteria 
(Staphylococcus aureus) and Gram-negative bacteria (Escherichia Coli), and for their fungicidal 
activity against Candida albicans. In this method, a standard 5 mm diameter sterilized filter paper disc 
impregnated with the compound (0.3 mg/0.1 ml of DMF) was placed on an agar plate seeded with the 
test organism. The plates were incubated for 24 h at 37 °C for bacteria and 28 °C for fungi. The zone of 
inhibition of bacterial and fungi growth around the disc was observed. 
4.6. In vitro antiplasmodial assay. Activity against P. falciparum chloroquine-sensitive 3D7 strains 
was assessed by following the procedure already described by Frederich et al.
29
 The parasites were 
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obtained from Prof. Grellier (Museum d’Histoire Naturelle, Paris, France). Each alkaloid and extract 
was applied in a series of eight three-fold dilutions (final concentrations ranging from 0.09 to 200 
µg/mL for an extract and from 0.02 to 50 µg/mL for a pure substance) on two rows of a 96-well 
microplate and were tested in duplicate (n = 2) or triplicate (n = 3). Parasite growth was estimated by 
determination of lactate dehydrogenase activity as described previously by Jonville et al.
30
 Artemisinin 
(98%, Sigma–Aldrich) was used as positive control (IC50 = 36 ±14 nM). All compounds were tested 3 
times (n = 3). 
4.7. In vitro cytotoxicity. The compounds were tested against breast carcinoma cell line MCF-7. The 
method applied is similar to that reported by Skehan et al.
31
 using 20 sulfo-rhodamine-B stain (SRB). 
Cells were plated in 96-multiwell plate (104 cells/well) for 24 h before treatment with the test 
compound to allow attachment of cell to the wall of the plate. Different concentrations of the 
compound under test (0, 1.0, 2.5, 5.0, and 10 mg/mL) were added to the cell monolayer in triplicate 
wells in individual dose, and monolayer cells were incubated with the compounds for 48 h at 37 °C and 
in atmosphere of 5% CO2. After 48 h, cells were fixed, washed and stained with SRB stain, excess stain 
was washed with acetic acid, and attached stain was recovered with Tris-EDTA buffer. Color intensity 
was measured in an ELISA reader, and the relation between surviving fraction and drug concentration 
is plotted to get the survival curve of the tumor cell line after the specified compound and the IC50 was 
calculated. 
4.8. Theoretical calculations. All the calculations were performed at DFT B3LYP level of theory. 
The geometries were fully optimized using the 6-31G(d) basis set. In order to perform stationary point 
characterization and to calculate zero-point vibrational energies and thermal corrections, vibrational 
frequencies were calculated at the same level of theory. The single point energies were obtained using 
the 6-311+G(d,p) basis set and tight convergence criteria. 
1
H NMR chemical shifts were calculated 
with Gauge-Independent Atomic Orbital (GIAO) method
32
 using corresponding TMS shielding 
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calculated at the same level of theory as the reference. The solvent effect was simulated within the 
polarized continuum model (PCM) with the default parameters for THF. 
Acknowledgments. FM thanks the Institut Universitaire de France and Rennes Métropole for financial 
support. NM, FC and FM thank Thermo Fisher for generous gift of 2,2,6,6-tetramethylpiperidine. 
Supplementary data. Supplementary data associated with this article can be found in the online 
version, at http://dx.doi.org/10.1016/j.tet.xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx. 
References and Notes 
1. (a) Hufford, C. D.; Liu, S.; Clark, A. M.; Oguntimein, B. O. J. Nat. Prod. 1987, 50, 961-964; 
(b) Wu, Y. C. Heterocycles 1989, 29, 463-475. 
2. (a) Koyama, J.; Morita, I.; Kobayashi, N.; Osakai, T.; Usuki, Y.; Taniguchi, M. Bioorg. Med. 
Chem. Lett. 2005, 15, 1079-1082; (b) Prachayasittikul, S.; Manam, P.; Chinworrungsee, M.; 
Isarankura-Na-Ayudhya, C.; Ruchirawat, S.; Prachayasittikul, V. Molecules 2009, 14, 4414-
4424; (c) Kraus, G. A.; Kempema, A. J. Nat. Prod. 2010, 73, 1967-1968; (d) Addla, D.; Bhima; 
Sridhar, B.; Devi, A.; Kantevari, S. Bioorg. Med. Chem. Lett. 2012, 22, 7475-7480. 
3. Mueller, D.; Davis, R. A.; Duffy, S.; Avery, V. M.; Camp, D.; Quinn, R. J. J. Nat. Prod. 2009, 
72, 1538-1540. 
4. (a) Manpadi, M.; Uglinskii, P. Y.; Rastogi, S. K.; Cotter, K. M.; Wong, Y.-S. C.; Anderson, L. 
A.; Ortega, A. J.; Van Slambrouck, S.; Steelant, W. F. A.; Rogelj, S.; Tongwa, P.; Antipin, M. 
Y.; Magedov, I. V.; Kornienko, A. Org. Biomol. Chem. 2007, 5, 3865-3872; (b) Pumsalid, K.; 
Thaisuchat, H.; Loetchutinat, C.; Nuntasaen, N.; Meepowpan, P.; Pompimon, W. Nat. Prod. 
Commun. 2010, 5, 1931-1934; (c) Banjerdpongchai, R.; Khaw-On, P.; Ristee, C.; Pompimon, 
W. Asian Pacific journal of cancer prevention : APJCP 2013, 14, 2637-2641. 
5. Shook, B. C.; Rassnick, S.; Osborne, M. C.; Davis, S.; Westover, L.; Boulet, J.; Hall, D.; 
Rupert, K. C.; Heintzelman, G. R.; Hansen, K.; Chakravarty, D.; Bullington, J. L.; Russell, R.; 
Branum, S.; Wells, K. M.; Damon, S.; Youells, S.; Li, X.; Beauchamp, D. A.; Palmer, D.; 
Reyes, M.; Demarest, K.; Tang, Y.-T.; Rhodes, K.; Jackson, P. F. J. Med. Chem. 2010, 53, 
8104-8115. 
6. (a) Bracher, F. Synlett 1991, 95-96; (b) Rebstock, A.-S.; Mongin, F.; Trecourt, F.; Queguiner, 
G. Tetrahedron 2003, 59, 4973-4977; (c) Rebstock, A.-S.; Mongin, F.; Trecourt, F.; Queguiner, 
G. Tetrahedron 2004, 60, 2181-2186; (d) Alessi, M.; Larkin, A. L.; Ogilvie, K. A.; Green, L. 
A.; Lai, S.; Lopez, S.; Snieckus, V. J. Org. Chem. 2007, 72, 1588-1594. 
7. (a) Tu, S.; Jiang, B.; Jia, R.; Zhang, J.; Zhang, Y. Tetrahedron Lett. 2007, 48, 1369-1374; (b) 
Li, Y.; Fan, W.; Xu, H.-W.; Jiang, B.; Wang, S.-L.; Tu, S.-J. Org. Biomol. Chem. 2013, 11, 
2417-2420. 
8. Dhara, S.; Ahmed, A.; Nandi, S.; Baitalik, S.; Ray, J. K. Tetrahedron Lett. 2013, 54, 63-65. 
9. (a) Mulvey, R. E.; Mongin, F.; Uchiyama, M.; Kondo, Y. Angew. Chem. Int. Ed. 2007, 46, 
3802-3824; (b) Mulvey, R. E. Acc. Chem. Res. 2009, 42, 743-755; (c) Haag, B.; Mosrin, M.; Ila, 
H.; Malakhov, V.; Knochel, P. Angew. Chem. Int. Ed. 2011, 50, 9794-9824; (d) Mongin, F.; 
 26 
Uchiyama, M. Curr. Org. Chem. 2011, 15, 2340-2361; (e) Mongin, F.; Harrison-Marchand, A. 
Chem. Rev. 2013, 113, 7563-7727. 
10. (a) Nguyen, T. T.; Chevallier, F.; Jouikov, V.; Mongin, F. Tetrahedron Lett. 2009, 50, 6787-
6790; (b) Nguyen, T. T.; Marquise, N.; Chevallier, F.; Mongin, F. Chem. Eur. J. 2011, 17, 
10405-10416; (c) Snégaroff, K.; Nguyen, T. T.; Marquise, N.; Halauko, Y. S.; Harford, P. J.; 
Roisnel, T.; Matulis, V. E.; Ivashkevich, O. A.; Chevallier, F.; Wheatley, A. E. H.; Gros, P. C.; 
Mongin, F. Chem. Eur. J. 2011, 17, 13284-13297; (d) Harford, P. J.; Peel, A. J.; Chevallier, F.; 
Takita, R.; Mongin, F.; Uchiyama, M.; Wheatley, A. E. H. Dalton Trans. 2014, 43, 14181-
14203. 
11. (a) Campeau, L.-C.; Parisien, M.; Jean, A.; Fagnou, K. J. Am. Chem. Soc. 2006, 128, 581-590; 
(b) Alberico, D.; Scott, M. E.; Lautens, M. Chem. Rev. 2007, 107, 174-238; (c) Ackermann, L.; 
Vicente, R.; Kapdi, A. R. Angew. Chem. Int. Ed. 2009, 48, 9792-9826. 
12. (a) Marquise, N.; Harford, P. J.; Chevallier, F.; Roisnel, T.; Wheatley, A. E. H.; Gros, P. C.; 
Mongin, F. Tetrahedron Lett. 2013, 54, 3154-3157; (b) Marquise, N.; Harford, P. J.; Chevallier, 
F.; Roisnel, T.; Dorcet, V.; Gagez, A.-L.; Sable, S.; Picot, L.; Thiery, V.; Wheatley, A. E. H.; 
Gros, P. C.; Mongin, F. Tetrahedron 2013, 69, 10123-10133. 
13. (a) Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457-2483; (b) Kotha, S.; Lahiri, K.; 
Kashinath, D. Tetrahedron 2002, 58, 9633-9695. 
14. Bräse, S.; de Meijere, A. Metal-Catalyzed Cross-Coupling Reactions (2nd Edition) 2004, 1, 
217-315. 
15. (a) Yadav, A. K.; Verbeeck, S.; Hostyn, S.; Franck, P.; Sergeyev, S.; Maes, B. U. W. Org. Lett. 
2013, 15, 1060-1063; (b) Fogg, D. E.; dos Santos, E. N. Coord. Chem. Rev. 2004, 248, 2365-
2379. 
16. Marquise, N.; Dorcet, V.; Chevallier, F.; Mongin, F. Org. Biomol. Chem. 2014, 12, 8138-8141. 
17. Netherton, M. R.; Fu, G. C. Org. Lett. 2001, 3, 4295-4298. 
18. Marzi, E.; Bigi, A.; Schlosser, M. Eur. J. Org. Chem. 2001, 1371-1376. 
19. Dai, X.; Chen, Y.; Garrell, S.; Liu, H.; Zhang, L.-K.; Palani, A.; Hughes, G.; Nargund, R. J. 
Org. Chem. 2013, 78, 7758-7763. 
20. (a) Maerten, E.; Sauthier, M.; Mortreux, A.; Castanet, Y. Tetrahedron 2006, 63, 682-689; (b) 
Brumfield, S.; Matasi, J. J.; Tulshian, D.; Czarniecki, M.; Greenlee, W.; Garlisi, C.; Qiu, H.; 
Devito, K.; Chen, S.-C.; Sun, Y.; Bertorelli, R.; Ansell, J.; Geiss, W.; Le, V.-D.; Martin, G. S.; 
Vellekoop, S. A.; Haber, J.; Allard, M. L. Bioorg. Med. Chem. Lett. 2011, 21, 7287-7290. 
21. Handy, S. T.; Zhang, Y. Chem. Commun. 2006, 299-301. 
22. Kadiyala, R. R.; Tilly, D.; Nagaradja, E.; Roisnel, T.; Matulis, V. E.; Ivashkevich, O. A.; 
Halauko, Y. S.; Chevallier, F.; Gros, P. C.; Mongin, F. Chem. Eur. J. 2013, 19, 7944-7960. 
23. Pink, R.; Hudson, A.; Mouries, M.-A.; Bendig, M. Nat. Rev. Drug Discov. 2005, 4, 727-740. 
24. Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. J. Org. Chem. 1997, 62, 7512-7515. 
25. Altomare, A.; Burla, M. C.; Camalli, M.; Cascarano, G. L.; Giacovazzo, C.; Guagliardi, A.; 
Moliterni, A. G. G.; Polidori, G.; Spagna, R. J. Appl. Crystallogr. 1999, 32, 115-119. 
26. Sheldrick, G. M. Acta Crystallogr., Sect. A 2008, A64, 112-122. 
27. Farrugia, L. J. J. Appl. Crystallogr. 2012, 45, 849-854. 
28. Bauer, A. W.; Kirby, W. M.; Sherris, J. C.; Turck, M. Am. J. Clin. Pathol. 1966, 45, 493-496. 
29. Frédérich, M.; Jacquier, M.-J.; Thepenier, P.; De Mol, P.; Tits, M.; Philippe, G.; Delaude, C.; 
Angenot, L.; Zeches-Hanrot, M. J. Nat. Prod. 2002, 65, 1381-1386. 
30. Jonville, M.-C.; Dive, G.; Angenot, L.; Bero, J.; Tits, M.; Ollivier, E.; Frédérich, M. 
Phytochemistry 2013, 87, 157-163. 
31. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; 
Bokesch, H.; Kenney, S.; Boyd, M. R. J. Natl. Cancer Inst. 1990, 82, 1107-1112. 
32. Ditchfield, R. Mol. Phys. 1974, 27, 789-807. 
